Kyowa Kirin Co ((KYKOF)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Kyowa Kirin Co. has initiated a Phase 1 clinical trial titled A Phase 1, Multicenter, Open-label, Non-randomized, Dose-escalation and Backfill Study of KK2223 in Participants With Relapsed or Refractory T-cell Non Hodgkin Lymphoma. The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KK2223 in adults with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
Intervention/Treatment: The intervention being tested is KK2223, an experimental drug administered via intravenous infusion. It is designed to treat patients with relapsed or refractory PTCL or CTCL by assessing its safety and effectiveness.
Study Design: This interventional study employs a non-randomized, sequential design. Participants will receive KK2223 in a stepwise manner, with treatment assignments and doses adjusted based on interim safety and efficacy analyses. The primary purpose is treatment, and there is no masking involved.
Study Timeline: The study is not yet recruiting, with initial submission on August 12, 2025, and the last update on September 17, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
Market Implications: The initiation of this study could influence Kyowa Kirin’s stock performance, as successful results may enhance investor confidence and market positioning. The study’s progress will be closely watched by investors and competitors in the oncology pharmaceutical sector.
The study is ongoing, with further details available on the ClinicalTrials portal.